Merck Animal Health Reaffirms its Commitment to the Poultry Industry and Future Poultry Talent at the International Production and Processing Expo (IPPE)

Rahway, NJ, January  24, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will showcase its portfolio of innovative solutions to advance the poultry industry as well as offer future talent development opportunities at the International Production and Processing Expo (IPPE) in Atlanta, GA from January 30 – February 1, 2024.

The company’s booth (#B7045) will feature live demonstrations of SenseHub™ Poultry, a wireless system that collects and analyzes real-time behavioral data that is fundamental to understanding bird health, welfare and performance. The data can be interpreted by specialist vets, nutritionists and other consultants, allowing farmers to make informed decisions on-farm. There will also be live demonstrations of INNOJECT® Pro, a chick vaccination system that combines eye and nasal drop administration with a dual subcutaneous injection to ensure that chicks are handled gently and safely, while increasing the accuracy of injection and greater stability during the vaccination process. Representatives from Merck Animal Health will be available to discuss the Company’s other innovations in poultry vaccines.

Immersive “Career Journey” Program Available for Future Talent

Merck Animal Health is committed to supporting emerging talent in the poultry industry. In line with this commitment, the Company will offer several opportunities for professional development:

• Minorities in Agriculture, Natural Resources, and Related Sciences (MANRRS) “Coffee & Chat with Leaders,” which will include a panel discussion with Maxim Nakhodko, head of global poultry, Merck Animal Health, Georgina Romero, director, Poultry, Merck Animal Health with Elizabeth Galbreath, senior specialist, future talent programs, Merck Animal Health as moderator, followed by a booth tour. (Wednesday, January 31, 9:15 a.m. to 10:30 a.m)
• Informal “Flash” Mentoring Sessions, which are quick and informal mentoring discussions focused on networking, answering questions about the industry and company, and resume editing (Tuesday, January 30, 11:30 a.m. to 12:30 p.m. and Wednesday, January 31, 12:30 p.m. to 1:30 p.m.)

“At Merck Animal Health we believe in nurturing the future talent of the poultry industry,” said Maxim Nakhodko, head of global poultry, Merck Animal Health “Through our programming, we aim to go beyond delivering excellence in animal health by offering opportunities to grow the many roles of the poultry profession, valuing and honoring each individual contribution in the context of the industry’s holistic impact.”

Hot Topics Live!

Hot Topics, a talk show where industry experts answer burning poultry questions while enjoying poultry foods and increasingly hot sauce will be taping live at the Merck Animal Health booth. Attendees can attend the live tapings with industry experts, who will discuss topics such as new trends in the hatchery, work-life balance, diversity, and insights on the future of respiratory challenges, including ILT and avian influenza.. Tapings take place on January 30 and 31.

*SenseHub™ Poultry  is not intended to diagnose, treat, cure, or prevent any disease in animals. For the diagnosis, treatment, cure, or prevention of disease in animals, you should consult your veterinarian. The accuracy of the data collected and presented through SenseHub™ Poultry is not intended to match that of medical devices or scientific measurement devices.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

---